Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

654.27 +29.55 (+4.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
63 64 Next >
News headline image
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades' ↗
Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol named as top trades. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks to Buy and Hold for a Decade ↗
These biotechs should benefit from their innovative ways. 
Via The Motley Fool
News headline image
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This... 
Via StockStory
Topics Stocks
News headline image
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder ↗
The U.S. 
Via Benzinga
News headline image
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Regeneron (REGN) Shares Are Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare... 
Via StockStory
News headline image
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
News headline image
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
What Does the Market Think About Regeneron Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Why Regeneron (REGN) Stock Is Down Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its... 
Via StockStory
News headline image
Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday? ↗
Wall Street paused on Tuesday after three straight sessions of strong gains that pushed major large-cap indices to fresh records. 
Via Benzinga
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stock in the S&P500 index ↗
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends. 
Via Chartmill
News headline image
1 S&P 500 Stock on Our Buy List and 2 We Turn Down
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
News headline image
FDA Delays Key Sanofi Multiple Sclerosis Drug Decision ↗
Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025. 
Via Benzinga
News headline image
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGENERON PHARMACEUTICALS (NASDAQ:REGN) Screens as a Top Value Stock with Strong Fundamentals ↗
Regeneron Pharmaceuticals (REGN) is a top value stock with a low P/E ratio, strong profitability, and excellent financial health, offering a potential margin of safety for investors. 
Via Chartmill
News headline image
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J? ↗
The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma. 
Via Investor's Business Daily
News headline image
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
News headline image
Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder ↗
Regeneron's Phase 3 trial of garetosmab showed a 90%+ reduction in new bone lesions for FOP, with no deaths and good safety over 56 weeks. 
Via Benzinga
Topics Death
News headline image
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.